Merck (MRK) Delays ProQuad Vaccine Once Again - DJN
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Join SI Premium – FREE
Merck & Co. (NYSE: MRK) is currently delaying orders of their ProQuad childhood vaccine, which has stopped be distributed since 2007, according to a Dow Jones Newswire.
The company previously planned on shipping the vaccine on February 15, 2010.
The delay, according to a spokesperson, is to supply other vaccines that share ingredients with ProQuad that are in more of demand currently. The other vaccines include Varivax for chickenpox, Zostavax for shingles and M-M-R II for measles, mumps and rubella.
ProQuad combines in one shot vaccines to protect against measles, mumps, rubella and chickenpox.
Sales peaked at $264 million in 2007, but then plunged as the company suspended new sales. The components of ProQuad are being supplied in the Varivax and M-M-R II vaccines.
Shares of Merck are down 2.79% in the late-afternoon session, to $37.64.
The company previously planned on shipping the vaccine on February 15, 2010.
The delay, according to a spokesperson, is to supply other vaccines that share ingredients with ProQuad that are in more of demand currently. The other vaccines include Varivax for chickenpox, Zostavax for shingles and M-M-R II for measles, mumps and rubella.
ProQuad combines in one shot vaccines to protect against measles, mumps, rubella and chickenpox.
Sales peaked at $264 million in 2007, but then plunged as the company suspended new sales. The components of ProQuad are being supplied in the Varivax and M-M-R II vaccines.
Shares of Merck are down 2.79% in the late-afternoon session, to $37.64.
You May Also Be Interested In
- Harvard discloses $2.2B SpaceX stake, over half its U.S. equity portfolio
- Morgan Stanley sees weaker China home prices amid sluggish sales
- Roblox user data suggests bookings above guidance range
Create E-mail Alert Related Categories
General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
